[{"id":"9f749ec0-9a4e-415b-87ef-80069ba67c42","acronym":"MA-CRC-II-018","url":"https://clinicaltrials.gov/study/NCT07478731","created_at":"2026-03-28T01:41:18.497Z","updated_at":"2026-03-28T01:41:18.497Z","phase":"Phase 2","brief_title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT07478731 - MA-CRC-II-018","lead_sponsor":"Hong Qiu","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/20/2025","start_date":" 12/20/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-17"},{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"5dee5c4e-4cac-4602-831a-304102b4edeb","acronym":"CRIT","url":"https://clinicaltrials.gov/study/NCT06908031","created_at":"2025-09-07T01:12:45.769Z","updated_at":"2025-09-07T01:12:45.769Z","phase":"Phase 2","brief_title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","source_id_and_acronym":"NCT06908031 - CRIT","lead_sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/02/2025","start_date":" 04/02/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-05-14"},{"id":"38f6d35a-64a3-4650-878e-b5837dc695fe","acronym":"BLENTI","url":"https://clinicaltrials.gov/study/NCT06940778","created_at":"2025-09-07T01:21:55.747Z","updated_at":"2025-09-07T01:21:55.747Z","phase":"","brief_title":"LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS","source_id_and_acronym":"NCT06940778 - BLENTI","lead_sponsor":"Hospital do Coracao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 273","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 12/10/2026","study_completion_date":" 12/10/2026","last_update_posted":"2025-04-27"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"2119d121-8980-4c19-8bce-e35f258e6e89","acronym":"EA2201","url":"https://clinicaltrials.gov/study/NCT04751370","created_at":"2021-02-12T13:55:42.607Z","updated_at":"2025-02-25T16:38:15.444Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04751370 - EA2201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 02/08/2022","start_date":" 02/08/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"7218af24-4289-464c-b642-c450f941d6b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01814501","created_at":"2021-01-18T08:03:17.318Z","updated_at":"2025-02-25T16:43:42.557Z","phase":"Phase 2","brief_title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","source_id_and_acronym":"NCT01814501","lead_sponsor":"John Hays","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 08/06/2018","primary_completion_date":" 08/06/2018","study_txt":" Completion: 08/06/2018","study_completion_date":" 08/06/2018","last_update_posted":"2025-02-05"},{"id":"79433067-e78e-4567-8836-adaaf499b67a","acronym":"SWOG S1613","url":"https://clinicaltrials.gov/study/NCT03365882","created_at":"2021-01-18T16:36:41.796Z","updated_at":"2025-02-25T13:52:26.960Z","phase":"Phase 2","brief_title":"S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03365882 - SWOG S1613","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • BRAF V600","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-01-14"},{"id":"456efb5b-1647-4ddb-add1-645fa0cf138f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06542588","created_at":"2025-02-26T07:12:34.732Z","updated_at":"2025-02-26T07:12:34.732Z","phase":"Phase 2","brief_title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","source_id_and_acronym":"NCT06542588","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-18"},{"id":"70cf91ce-5494-4e3c-8936-16d7a4476273","acronym":"TORCH-R","url":"https://clinicaltrials.gov/study/NCT05628038","created_at":"2025-03-03T11:15:37.220Z","updated_at":"2025-03-03T11:15:37.220Z","phase":"Phase 2","brief_title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","source_id_and_acronym":"NCT05628038 - TORCH-R","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Tomudex (raltitrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-10-01"},{"id":"d539a3d8-c8c8-4055-bc40-3d443b47db3d","acronym":"IGLarc","url":"https://clinicaltrials.gov/study/NCT06616870","created_at":"2025-02-26T14:59:10.870Z","updated_at":"2025-02-26T14:59:10.870Z","phase":"","brief_title":"Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT06616870 - IGLarc","lead_sponsor":"Centro di Riferimento Oncologico - Aviano","biomarkers":" SMAD3","pipe":"","alterations":" ","tags":["SMAD3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/03/2024","start_date":" 10/03/2024","primary_txt":" Primary completion: 10/03/2029","primary_completion_date":" 10/03/2029","study_txt":" Completion: 10/03/2029","study_completion_date":" 10/03/2029","last_update_posted":"2024-09-27"},{"id":"1844ac4c-7706-4bda-83c3-f18f6ab3c4e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06577194","created_at":"2025-02-27T08:16:49.348Z","updated_at":"2025-02-27T08:16:49.348Z","phase":"Phase 2","brief_title":"A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Concurrent With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT06577194","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-08-29"},{"id":"2733b16c-4744-4169-8120-2555bfcf29cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867799","created_at":"2021-01-18T19:04:28.946Z","updated_at":"2024-07-02T16:34:26.092Z","phase":"Phase 2","brief_title":"iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","source_id_and_acronym":"NCT03867799","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 10/21/2022","primary_completion_date":" 10/21/2022","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-06-14"},{"id":"51654522-b1f1-419a-bdd1-387537311c21","acronym":"NCI-2022-02494","url":"https://clinicaltrials.gov/study/NCT05308446","created_at":"2022-04-04T14:52:50.907Z","updated_at":"2024-07-02T16:34:37.234Z","phase":"Phase 2","brief_title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","source_id_and_acronym":"NCT05308446 - NCI-2022-02494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-06-07"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"0177e6bb-9b98-4e6c-9452-eda5749c5709","acronym":"EXACT","url":"https://clinicaltrials.gov/study/NCT03975491","created_at":"2021-01-18T19:33:09.634Z","updated_at":"2024-07-02T16:35:00.218Z","phase":"","brief_title":"The Exercise And Colorectal Cancer Treatment Trial","source_id_and_acronym":"NCT03975491 - EXACT","lead_sponsor":"Pennington Biomedical Research Center","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/16/2019","start_date":" 08/16/2019","primary_txt":" Primary completion: 05/16/2023","primary_completion_date":" 05/16/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-30"},{"id":"b72569e3-5b2c-4b6d-a8ef-d641494aa19c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04357587","created_at":"2021-01-18T21:04:15.436Z","updated_at":"2025-02-25T16:25:47.207Z","phase":"Phase 1","brief_title":"Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer","source_id_and_acronym":"NCT04357587","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" MSI • CEACAM5","pipe":"","alterations":" ","tags":["MSI • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 09/25/2023","primary_completion_date":" 09/25/2023","study_txt":" Completion: 09/25/2023","study_completion_date":" 09/25/2023","last_update_posted":"2024-05-29"},{"id":"e12d07d3-5b9e-4f7e-a555-ab221f3e7d50","acronym":"SUNRISE","url":"https://clinicaltrials.gov/study/NCT03714490","created_at":"2024-06-01T04:17:15.667Z","updated_at":"2024-07-02T16:35:00.347Z","phase":"Phase 2","brief_title":"MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer","source_id_and_acronym":"NCT03714490 - SUNRISE","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • TP53 • PTEN","pipe":"","alterations":" ","tags":["EGFR • TP53 • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/23/2018","start_date":" 10/23/2018","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-29"},{"id":"4ddeafce-3b8e-4b29-b230-0788f469d7b7","acronym":"PRORECT","url":"https://clinicaltrials.gov/study/NCT04525989","created_at":"2024-03-05T21:32:32.859Z","updated_at":"2024-07-02T16:35:02.544Z","phase":"","brief_title":"Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)","source_id_and_acronym":"NCT04525989 - PRORECT","lead_sponsor":"Alexander Valdman","biomarkers":" CEACAM5 • FOXP3","pipe":"","alterations":" ","tags":["CEACAM5 • FOXP3"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-05-20"},{"id":"affb8663-7021-4d12-a915-dc83a9648d38","acronym":"mRCAT","url":"https://clinicaltrials.gov/study/NCT05972655","created_at":"2023-08-02T14:08:57.261Z","updated_at":"2024-07-02T16:35:04.308Z","phase":"Phase 2","brief_title":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","source_id_and_acronym":"NCT05972655 - mRCAT","lead_sponsor":"Sir Run Run Shaw Hospital","biomarkers":" MSI • MSH6 • MSH2","pipe":"","alterations":" ","tags":["MSI • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/02/2023","start_date":" 08/02/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-10"},{"id":"4bf9de82-bc5d-4f41-96c1-1ff5dcf642d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672524","created_at":"2023-01-05T14:58:33.539Z","updated_at":"2024-07-02T16:35:09.423Z","phase":"Phase 2","brief_title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","source_id_and_acronym":"NCT05672524","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"},{"id":"75412222-112b-4fb1-9051-534390fb4a85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554836","created_at":"2021-01-18T21:46:30.517Z","updated_at":"2024-07-02T16:35:10.447Z","phase":"Phase 2","brief_title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","source_id_and_acronym":"NCT04554836","lead_sponsor":"TheraOp","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 07/22/2024","primary_completion_date":" 07/22/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-04-10"}]